

Date: October 08, 2021

| To, | To, |
|--|--|
| The Manager, Listing Department, | The Department of Corporate Service, |
| National Stock Exchange of India | BSE Limited, |
| Limited, | 1 st Floor, New Trading Ring, Rotunda |
| Exchange Plaza, C - 1, Block - G, Bandra - | Building, Phiroze Jeejeebhoy Tower, |
| Kurla Complex, Bandra (E), Mumbai-400 051. | Dalal Street, Mumbai – 400 001. |
| Scrip Code - LINCOLN | Scrip Code - 531633 |

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 — Media Release on Lincoln Pharmaceuticals Ltd plans receives approval from Australian Regulator, TGA.

With reference to the above captioned subject, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Press Release titled "Lincoln Pharmaceuticals Ltd receives approval from Australian Regulator, TGA."

We request you to take the same on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LTD

COMPANY SECRETARY

COMPLIANCE OFFICER

Encl: A/A









Media Release

Lincoln Pharmaceuticals Ltd receives approval from Australian Regulator, TGA

TGA and EU GMP approval will strengthen company's presence in the regulated markets

Highlights:-

- Approvals will increase company's business network to 90 plus countries; Currently exports to 60 plus countries:
- Export Sales have increased to 65% in FY 21 which was 11% in FY 11;
- Company plans to enter Australian markets soon with Dermatology, Gastro and Pain Management products and expand gradually.

Ahmedabad, October 8, 2021: Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has received approval from Australia's medicines and medical devices regulator - Therapeutic Goods Administration (TGA). Company's manufacturing facility in Khatraj, Gujarat received the GMP clearance from TGA for all three departments Tablet, Capsule and Cream & Ointment, which will cover wide range of Pharmaceutical Formulation manufactured by the Company. Company looks to enter the Australian markets soon with its dermatology, gastro and pain management products and gradually expand product portfolio. The certification will be valid till June 2023.

TGA and EU GMP approval will strengthen company's presence in the regulated markets. In May 2020, company had received European Union (EU) GMP certification from Germany FDA for its manufacturing facility which allows the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries

The company manufactures wide-range of drugs at its Khatraj facility and includes antiinfective, respiratory system, gynaecology, dermatology, gastro, pain management, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.

Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "TGA and EU GMP approval are important stepping stone in the journey of the company and will help to expand its presence in more regulated markets. TGA and EU GMP approvals are result of stringent quality and compliance norms followed at Lincoln Pharma across all departments especially the R&D and compliance. Over the years, company has seen good traction in the export business, which is expected to get further boost once TGA & EU operations begins. The certification will allow us to address the growing needs of patients in the regulated markets and provide affordable and innovative medicines."

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com







With the TGA & EU certification, company will expand its business network to 90 plus countries. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia and has got many product registrations in these countries and is also awarded with number of global tenders.

Export business of the company has shown remarkable growth in the last few years and had increased to 65% of total sales in FY21 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. For the FY21, exports grew 18.4% to Rs. 270 crore.


"For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management to complement its strong presence in acute segment. Going forward, we are confident to improve our growth numbers of revenue, margins and profitability in FY22. Our strategic growth initiatives, product and geographical expansion, operational efficiency and debt free status are likely to maximise value for all stakeholders in the near to medium term," said Mr. Patel.

Over the last 5 years, Lincoln Pharmaceuticals Ltd has delivered a robust 20% plus CAGR in profits and higher single digit growth in sales. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no term debt and healthy return ratios. Backed by improvement in the company's financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company's long-term and short-term bank facilities to A and A1 respectively.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has filled 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

_____ ***___





E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com









About Lincoln Pharmaceuticals Ltd https://www.lincolnpharma.com/

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi / Rupesh Panchal ColdCoco Consultancy, Ahmedabad 9099030184 / 9925023103 qopal@coldcococonsultancy.com rupesh@coldcococonsultancy.com

Darshit A. Shah (CFO)

Lincoln Pharmaceuticals Limited, Ahmedabad +91-79-4107-8048 darshit@lincolnpharma.com

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com

Factory: 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta.: Kalol, Dist. Gandhinagar, (Guj.) | Phone: +91-79-49135000 | E-mail: khatraj@lincolnpharma.com



